Tag: Boehringer Ingelheim
Boehringer bets up to $1B on RNA splicing targets from Envisagenics
The New York company will mine alternative splicing for tumor-specific targets that drug makers can turn into therapies.
Owkin’s AI scientist lands at Boehringer Ingelheim labs
Boehringer Ingelheim licenses Owkin's K Pro AI scientist and multimodal oncology and immunology data.
Boehringer Ingelheim taps Immunai AI platform in $15 million deal
Boehringer Ingelheim pays $15M for Immunai's AI platform to find shared T-cell targets across cancer and autoimmune disease.